In xenograft models of lung, pancreas and HNSCC, treatment with a novel anti-FAP monoclonal antibody-maytansinoid conjugate known as FAP5-DM1, conferred durable suppression of tumor development with good tolerability [92]. This evidence concerns the gene FAP and head and neck squamous cell carcinoma.